Regarding erlotinib-resistance, the dual TβRI and TβRII selective inhibitor LY2109761 developed by Eli Lilly and Company was also assayed in lung cancer cells in one of the reviewed articles [100]. The gene discussed is TGFBR1; the disease is lung carcinoma.